Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering ...
William Blair restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report ...
Study Finds on MSN16h
Tiny lightning bolts discovered in water droplets—and it might explain how life began on EarthEarth might be creating microscopic lightning bolts—and this electrical phenomenon could have sparked the chemistry of life ...
A live audio webcast of the company presentation will be available on the "Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject ...
Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 64 ...
Everest and their record-breaking ascent attempt - Minister for Veterans and People Al Carns is among the team of ex-Special ...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has earned an average rating of “Buy” from the nine ratings firms that are covering the company, Ratings reports. Nine equities research ...
Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD ...
BURNABY, British Columbia — BURNABY, British Columbia — Xenon Pharmaceuticals Inc. (XENE) on Thursday reported a loss of $65.7 million in its fourth quarter. On a per-share basis, the Burnaby, British ...
Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $42 from $43 and keeps an Outperform rating on the shares. Most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback